Document Detail

Prognostic significance of plasma osteopontin levels in patients with chronic stable angina.
MedLine Citation:
PMID:  16421174     Owner:  NLM     Status:  MEDLINE    
AIMS: Levels of the secreted glycophosphoprotein osteopontin (OPN) have been associated with the presence and extent of coronary artery disease (CAD). The present study assessed the relationship between plasma OPN concentrations and prognosis in patients with chronic stable angina (CSA). METHODS AND RESULTS: OPN was measured in baseline plasma samples from 799 patients with stable angina pectoris and angiographically documented CAD. Participants were prospectively followed-up for a median of 2.7 years (maximum 4.1 years). The primary study endpoint was the composite of non-fatal myocardial infarction and death from cardiovascular causes. In the univariate Cox proportional hazard analysis, the log-transformed OPN level [hazard ratio (HR) 1.79, 95% CI 1.35-2.36, P < 0.001] was significantly related to adverse outcome. In addition, hypertension, levels of C-reactive protein, and statin use were associated with future adverse events. Levels of OPN (HR, 1.88; P < 0.001) and C-reactive protein (HR, 1.42; P = 0.003), as well as the presence of hypertension (HR, 2.39; P = 0.008) remained statistically significant, independent predictors of adverse cardiovascular outcome in a multivariable Cox proportional hazard analysis. CONCLUSION: Baseline levels of OPN are an independent predictor of future adverse cardiac events in patients with CSA and may be useful for risk stratification.
Piercarlo Minoretti; Colomba Falcone; Margherita Calcagnino; Enzo Emanuele; Maria P Buzzi; Enrico Coen; Diego Geroldi
Related Documents :
12933374 - Calcium channel blockers for reducing cardiac morbidity after noncardiac surgery: a met...
2065684 - Microalbuminuria is an early response following acute myocardial infarction.
23687124 - Arrhythmic complications after electrical cardioversion of acute atrial fibrillation: t...
15660034 - Prognostic impact of body weight and abdominal obesity in women and men with cardiovasc...
1597894 - Does the clinical evaluation of the cardiac status predict outcome in patients with abd...
16375624 - Conivaptan: a selective vasopressin antagonist for the treatment of heart failure.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2006-01-18
Journal Detail:
Title:  European heart journal     Volume:  27     ISSN:  0195-668X     ISO Abbreviation:  Eur. Heart J.     Publication Date:  2006 Apr 
Date Detail:
Created Date:  2006-03-16     Completed Date:  2006-07-31     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  8006263     Medline TA:  Eur Heart J     Country:  England    
Other Details:
Languages:  eng     Pagination:  802-7     Citation Subset:  IM    
Department of Cardiology, Alessandro Manzoni Hospital of Lecco, Italy.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Angina Pectoris / blood*,  mortality
Chronic Disease
Coronary Artery Disease / blood*
Middle Aged
Prospective Studies
Risk Assessment
Risk Factors
Sialoglycoproteins / blood*
Reg. No./Substance:
0/SPP1 protein, human; 0/Sialoglycoproteins; 106441-73-0/Osteopontin
Comment In:
Eur Heart J. 2006 Apr;27(7):766-7   [PMID:  16434412 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  The CAREGENE study: polymorphisms of the beta1-adrenoceptor gene and aerobic power in coronary arter...
Next Document:  Clinical predictors and prognostic significance of electrical storm in patients with implantable car...